// Evidence Grader
Claim grades, A through F
Every major genomics claim in this course gets a transparent grade — from clinically established interventions to outright misleading marketing. Use this dashboard to audit what's settled, what's preliminary, and what's hype.
A
Clinically established
B
Supported, context-specific
C
Promising, preliminary
D
Plausible, unproven
E
Popular, weak support
F
Misleading or false
Filtered:
F
ENCODE's '80% functional' claim means most of the genome is biologically essential
ENCODE used a maximally permissive 'biochemical activity' definition. Comparative-genomics estimates put functionally constrained sequence at ~8–15%.
Module 01 · The Human Genome at Scale →F
MTHFR genotyping is clinically useful for thrombosis or psychiatric workups
ACMG explicitly recommends against; no clinical utility.
Module 04 · Pharmacogenomics in Practice →F
European-trained PRS perform equally well in African-ancestry individuals
Documented R² loss of ~50% or more across most disease scores.
Module 06 · Polygenic Risk & Early Warning →F
Germline CRISPR editing of human embryos for medical indications is safe and ready for clinical use
He Jiankui case was scientifically and ethically condemned; no consensus body endorses germline editing for clinical use.
Module 09 · CRISPR Therapeutics: From Casgevy to In Vivo →F
AAV gene therapy is generally re-dosable
Pre-existing and induced neutralizing antibodies preclude conventional re-dosing for current capsids; engineered evader capsids and IgG-cleaving enzymes are research-stage.
Module 10 · Beyond CRISPR: ASO, siRNA, mRNA, AAV, and Cell Therapy →F
GINA fully protects US patients against genomic discrimination
GINA covers health insurance and employment only; life, disability, and long-term-care insurers may use genetic information.
Module 12 · Ethics, Equity, and the Germline Question →